Consun Pharmaceutical Group Limited (Consun Pharma) disclosed a small-scale on-market share buyback on 11 June 2026, further utilising its current repurchase mandate.

The company acquired 27,000 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 13.52 to HKD 13.63, translating into a volume-weighted average cost of HKD 13.55 per share and an aggregate outlay of HKD 0.37 million.

Key post-transaction metrics: • Issued shares (excluding treasury shares) declined to 840.29 million, a marginal reduction of 0.0032 %. • Treasury share balance increased to 1.26 million shares. • Total shares in issue (including treasury shares) remained unchanged at 841.55 million.

Mandate utilisation: • Shareholders authorised the board on 26 May 2026 to repurchase up to 84.12 million shares. • Cumulative buybacks under this mandate now total 0.91 million shares, representing 1.08 % of the company’s issued share capital at mandate date. • Approximately 83.21 million shares—98.9 % of the approved limit—remain available for future repurchases.

Pursuant to Hong Kong listing rules, Consun Pharma is restricted from issuing new shares or disposing of treasury shares until 11 July 2026, 30 days after the latest repurchase.